Active Ingredient History
Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Epidermal Growth Factor (Phase 3)
Head and Neck Neoplasms (Phase 2)
Hemangiosarcoma (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1)
Neoplasm Metastasis (Early Phase 1)
Neoplasms (Phase 2)
Sarcoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue